Travere Therapeutics (TVTX) Projected to Post Quarterly Earnings on Thursday

Travere Therapeutics (NASDAQ:TVTX) is anticipated to release its Q1 2025 earnings data before the market opens on Thursday, May 1st. Analysts expect Travere Therapeutics to post earnings of ($0.54) per share and revenue of $77.44 million for the quarter.

Travere Therapeutics (NASDAQ:TVTX) last posted its quarterly earnings results on Thursday, February 20th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($0.15). Travere Therapeutics had a negative net margin of 137.90% and a negative return on equity of 1,636.87%. The business had revenue of $74.79 million during the quarter, compared to analyst estimates of $72.38 million. On average, analysts expect Travere Therapeutics to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Travere Therapeutics Stock Performance

NASDAQ TVTX opened at $19.36 on Tuesday. Travere Therapeutics has a 12-month low of $5.24 and a 12-month high of $25.29. The company has a current ratio of 1.71, a quick ratio of 1.68 and a debt-to-equity ratio of 24.96. The company has a market cap of $1.72 billion, a P/E ratio of -4.72 and a beta of 0.84. The company has a fifty day simple moving average of $18.17 and a 200 day simple moving average of $18.67.

Analyst Ratings Changes

Several research firms have commented on TVTX. Scotiabank reiterated an “outperform” rating on shares of Travere Therapeutics in a research note on Friday, April 11th. Bank of America raised their price target on shares of Travere Therapeutics from $29.00 to $31.00 and gave the stock a “buy” rating in a research note on Tuesday, April 1st. HC Wainwright raised their price target on shares of Travere Therapeutics from $18.00 to $22.00 and gave the stock a “buy” rating in a research note on Wednesday, January 15th. JPMorgan Chase & Co. raised their price target on shares of Travere Therapeutics from $42.00 to $44.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 26th. Finally, Guggenheim restated a “buy” rating and set a $47.00 price target on shares of Travere Therapeutics in a research note on Monday, April 14th. One research analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $32.08.

Insiders Place Their Bets

In related news, insider Peter Heerma sold 3,074 shares of Travere Therapeutics stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $25.00, for a total value of $76,850.00. Following the completion of the sale, the insider now owns 127,634 shares of the company’s stock, valued at $3,190,850. The trade was a 2.35 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Eric M. Dube sold 11,375 shares of Travere Therapeutics stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $24.04, for a total value of $273,455.00. Following the completion of the sale, the chief executive officer now directly owns 419,173 shares of the company’s stock, valued at $10,076,918.92. The trade was a 2.64 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 156,330 shares of company stock valued at $3,507,377. Corporate insiders own 3.75% of the company’s stock.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.